| Expression pattern: |
UP |
| Associated gene: |
- |
| Associated microRNA: |
- |
| Biological function: |
circFADS2 is identified as an oncogenic biomarker and potential prognostic factor in CRC; elevated expression is associated with malignant progression features including larger tumor size, poor differentiation, deeper invasion, lymphatic and distant metastasis, late TNM stage, and poor outcome. |
| Molecular mechanism: |
The underlying regulatory mechanism was not clarified; the study mainly reports circFADS2 expression and prognostic associations in CRC. |
| Biological pathway or process: |
invasion (promotes); metastasis (promotes); other pathway/process (promotes) |
| Detected method: |
Q
M
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; RT-qPCR; Microarray; Clinical Sample Validation; Survival Analysis; ROC Analysis; Bioinformatics Analysis |
| Clinical significance: |
High circFADS2 expression is associated with shorter overall survival, poor prognosis, and may serve as an independent prognostic biomarker; combined circFADS2 expression and TNM stage improves prognostic prediction. |
| Description: |
circFADS2, also named hsa_circ_022382 in the paper, is derived from the human FADS2 gene and is significantly up-regulated in CRC tissues. Its elevated expression correlates with aggressive clinicopathological features and shorter overall survival, supporting its role as a potential oncogenic prognostic biomarker for CRC. The study did not experimentally define a molecular regulatory mechanism. |
| Confidence score: |
0.6895 |